ILSUNG IS CO., LTD. Logo

ILSUNG IS CO., LTD.

Develops pharmaceuticals like antibiotics and anesthetics, expanding into CNS and GI therapies.

003120 | KO

Overview

Corporate Details

ISIN(s):
KR7003120003
LEI:
Country:
South Korea
Address:
서울특별시 용산구 원효로84길 9, 서울특별시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Based on available data, ILSUNG IS CO., LTD. is a pharmaceutical company. The firm's core focus is on antibiotics, cardiovascular drugs, anesthetics, and contrast media. It is actively expanding its therapeutic areas to include gastrointestinal (GI), central nervous system (CNS), and other related fields. The company's activities involve managing drug pipelines, conducting clinical trials, and developing patented technologies in the nervous system disease domain. Note: No information was found to support the premise of the company being a financial data provider; all relevant search results indicate a pharmaceutical business.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-14 00:00
Annual Report
[기재정정]사업보고서 (2024.12)
Korean 1.2 MB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 922.9 KB
2025-07-22 00:00
Major Shareholding Notification
최대주주등소유주식변동신고서
Korean 44.4 KB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 833.6 KB
2025-04-28 00:00
Board/Management Information
대표이사(대표집행임원)변경(안내공시)
Korean 6.4 KB
2025-04-14 00:00
Annual Report
[기재정정]사업보고서 (2024.12)
Korean 1.2 MB
2025-03-21 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 29.3 KB
2025-03-21 00:00
Board/Management Information
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Korean 9.9 KB
2025-03-13 00:00
Audit Report / Information
감사보고서제출
Korean 11.3 KB
2025-03-13 00:00
Annual Report
[첨부추가]사업보고서 (2024.12)
Korean 1.2 MB
2025-03-06 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 81.8 KB
2025-02-20 00:00
Pre-Annual General Meeting Information
주주총회집중일개최사유신고
Korean 4.3 KB
2025-02-20 00:00
Pre-Annual General Meeting Information
주주총회소집결의
Korean 16.2 KB
2025-02-20 00:00
Notice of Dividend Amount
현금ㆍ현물배당결정
Korean 9.4 KB
2025-02-05 00:00
Earnings Release
매출액또는손익구조30%(대규모법인은15%)이상변경
Korean 11.5 KB

Automate Your Workflow. Get a real-time feed of all ILSUNG IS CO., LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for ILSUNG IS CO., LTD.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for ILSUNG IS CO., LTD. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

ArcticZymes Technologies Logo
Develops novel enzymes from Arctic organisms for diagnostics, therapeutics, and biopharma.
Norway
AZT
Arcturus Therapeutics Holdings Inc. Logo
Develops mRNA therapeutics and vaccines for rare respiratory, liver, and infectious diseases.
United States of America
ARCT
Arcus Biosciences, Inc. Logo
A clinical-stage biopharma developing small molecule and antibody combination therapies for cancer.
United States of America
RCUS
Arcutis Biotherapeutics, Inc. Logo
Develops and commercializes non-steroidal therapies for immune-mediated skin diseases.
United States of America
ARQT
ARDELYX, INC. Logo
Biopharma developing first-in-class drugs for cardiorenal and GI diseases like IBS-C and CKD.
United States of America
ARDX
ARECOR THERAPEUTICS PLC Logo
Biopharma firm enhancing drugs via reformulation for diabetes and pharmaceutical partners.
United Kingdom
AREC
argenx SE Logo
Develops first-in-class antibody therapies for severe autoimmune diseases.
Netherlands
1AE
Armata Pharmaceuticals, Inc. Logo
Developing bacteriophage therapeutics for antibiotic-resistant infections.
United States of America
ARMP
AroCell AB Logo
Develops and markets diagnostic tests for monitoring cancer and bacterial diseases.
Sweden
AROC
ArriVent BioPharma, Inc. Logo
A clinical-stage biopharma developing in-licensed oncology drugs for difficult-to-treat diseases.
United States of America
AVBP

Talk to a Data Expert

Have a question? We'll get back to you promptly.